Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

Enzo Biochem stock opened at $0.98 on Friday. The stock has a 50-day simple moving average of $1.12 and a 200-day simple moving average of $1.12. Enzo Biochem has a fifty-two week low of $0.93 and a fifty-two week high of $1.50.

Enzo Biochem Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 15th will be issued a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a dividend yield of 41.03%. The ex-dividend date of this dividend is Friday, November 15th.

Hedge Funds Weigh In On Enzo Biochem

A number of hedge funds and other institutional investors have recently bought and sold shares of ENZ. XTX Topco Ltd boosted its holdings in Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares in the last quarter. BBR Partners LLC purchased a new stake in shares of Enzo Biochem in the third quarter valued at $112,000. Geode Capital Management LLC increased its stake in shares of Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares in the last quarter. 36.90% of the stock is currently owned by hedge funds and other institutional investors.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.